Quality Technical Agreements for Canadian CMOs: What Health Canada GMP Actually Requires

A manufacturer we spoke with recently had a solid CMO relationship — five years, no major deviations, reliable batch turnaround. Then a Health Canada inspector reviewed their Quality Technical Agreement during a routine facility audit. The observation that came back wasn’t about a process failure or a contamination risk. It was about a single clause: who actually held batch release authority.

That observation cascaded into a six-week remediation process, a supplementary submission, and an uncomfortable conversation with their CMO partner. The QTA had been drafted years earlier, signed off, and never touched since. And on that one question — who signs off on a batch before it ships to Canadian patients — it was genuinely ambiguous.

Quality Technical Agreements are the scaffolding of any pharmaceutical outsourcing relationship. But too many manufacturers treat them as a box-ticking exercise. Here’s what Health Canada GMP actually requires, and where the gaps consistently show up.

What Health Canada GMP Says About Contract Manufacturing

The regulatory foundation is Section C.02.012 of the Food and Drug Regulations, Part C, Division 2. That section requires a written contract defining the GMP responsibilities of each party when manufacturing is performed under contract. It’s not optional. It’s not a recommendation. And Health Canada’s Good Manufacturing Practices guidance document — GUI-0001, now harmonised with PIC/S PE 009-16 — reinforces this with specific language about what that written contract must address.

ICH Q10, the Pharmaceutical Quality System guideline adopted by Health Canada, adds the clearest framing in Section 2.7: outsourced activities and purchased materials shall be controlled. The guideline requires that quality agreements define the responsibilities of both the contract giver and contract acceptor, covering manufacturing, testing, and quality system interactions. Health Canada reviewers treat ICH Q10 as part of the expected quality standard — not as aspirational guidance.

What this means in practice: a QTA that simply lists activities performed by the CMO doesn’t satisfy these requirements. Inspectors are looking for explicit allocation of every GMP responsibility. Not “the CMO handles manufacturing” — but precisely who reviews batch records, who investigates OOS results, who initiates a Health Canada notification, and who has the authority to reject a batch.

What a Canada GMP-Compliant QTA Must Actually Cover

There’s no standard template mandated by Health Canada, which means the responsibility for completeness falls entirely on the contract giver. In our experience reviewing QTAs for Canadian manufacturers, the most robust agreements consistently address these eight areas:

1. Defined Scope of Manufacturing Activities The QTA should specify exactly what the CMO is contracted to do — not in broad strokes, but at the unit operation level. Granulation? Compression? Coating? Primary packaging? Secondary labelling? Each activity that touches the product needs to be in scope. Activities explicitly excluded matter just as much — inspectors use omissions to probe whether the contract giver genuinely understands the manufacturing chain.

2. Batch Release Authority This is the single most common ambiguity in QTAs, and it’s the one Health Canada inspectors probe hardest. The agreement must state unambiguously which party holds Quality Unit authority to release a batch for Canadian distribution. The contract giver retains regulatory accountability to Health Canada regardless of what the QTA says — but internally, the document must make clear who performs each review step and who executes final release.

3. Change Control and Regulatory Submission Triggers Any manufacturing change that could affect product quality, safety, or efficacy may require a supplement to the New Drug Submission or Abbreviated NDS — potentially a Level II or Level III supplement under Health Canada’s Post-Notice of Compliance Changes guidance. The QTA must define who at the CMO is responsible for flagging changes, within what timeframe, and who at the sponsor makes the regulatory filing decision. Without this, changes slip through that should have triggered a submission.

4. Out-of-Specification and Deviation Management When a batch fails specification, the investigation clock starts immediately. The QTA needs to specify notification timelines — 24 to 48 hours is typical in well-drafted agreements — responsibility for leading the OOS investigation, and who makes the final batch disposition decision. The same logic applies to manufacturing deviations: the agreement should state which party completes the deviation report and which party reviews it for adequacy.

5. CAPA Responsibility Allocation Corrective and Preventive Action ownership gets murky in contract relationships. The QTA should specify who opens CAPAs, who sets target dates, and who verifies effectiveness. Where both parties have responsibilities — for example, the CMO owns the corrective action but the contract giver validates the process change — this should be written explicitly. “Both parties will cooperate” is not sufficient language and will not satisfy an inspector.

6. Audit Rights and Health Canada Inspection Cooperation Health Canada inspectors have the right to inspect any party in the manufacturing chain. Your QTA should give the contract giver explicit rights to conduct GMP audits of the CMO — with reasonable notice defined (typically 10 to 15 business days for scheduled audits, shorter windows for for-cause inspections). Equally important: the QTA should obligate the CMO to notify the contract giver within 24 hours of receiving notice of a Health Canada inspection, and to provide copies of relevant inspection observations.

7. Document Retention and Access Under Part C, Division 2 of the Food and Drug Regulations, batch records must be retained for at least one year after the expiry date of the product, or two years after the date of sale, whichever is longer. The QTA must specify where batch records are held, who bears responsibility for retention at the CMO site, and how the contract giver can access records on demand — including in the event the CMO relationship terminates.

8. Annual Review and Version Control A QTA that doesn’t reflect current manufacturing reality is arguably worse than no agreement at all. The document should include a provision for review at least annually, or following any significant manufacturing change, quality system update, or regulatory amendment. Every reviewed-and-reaffirmed version should be dated, signed by Quality leads at both organisations, and archived with the prior versions intact.

Where Health Canada Inspectors Find the Gaps

In our experience supporting manufacturers through Health Canada facility audits, the observations related to QTAs cluster around four recurring issues.

Stale agreements. The CMO added a second manufacturing site two years ago. The QTA still references only the original facility. Or the product was reformulated, changing the primary packaging line, but the QTA was never updated. Inspectors compare QTA scope to actual manufacturing activities — discrepancies are flagged immediately, and they raise broader questions about the contract giver’s quality oversight capability.

Ambiguous release language. Phrases like “the Quality Unit of each party shall review and approve” give inspectors nothing useful. Whose signature goes on the Certificate of Analysis? Who enters the final release record in the ERP system? These need to be named roles, not abstract organisational units. If the CMO has a Qualified Person who performs the physical release step, name that function explicitly.

Missing notification obligations. When a Canadian CMO receives a regulatory observation from Health Canada — an inspection finding, a request for corrective action — the contract giver often has no idea until weeks later. The QTA should require the CMO to notify the contract giver within 48 hours for any regulatory communication from Health Canada that touches the contracted product. This is a protection for both parties.

No CAPA visibility. If a deviation occurs at the CMO site and a CAPA is opened, the contract giver is frequently left out of the effectiveness verification step. Health Canada expects the contract giver’s Quality Unit to maintain oversight — which requires access to CAPA records and a defined review mechanism. Agreements that leave this undefined leave the contract giver with a blind spot that inspectors will find.

Keeping Your QTA Current as Manufacturing Evolves

Post-approval change management is where the QTA goes from a static document to an active regulatory tool. Under Health Canada’s post-market guidance, certain changes to a drug product’s manufacturing process require advance notification or approval before implementation. The QTA defines the internal workflow that ensures those requirements are met.

The practical approach: include a change control notification clause obligating the CMO to submit a written change proposal to the contract giver’s regulatory team before implementing any change that could affect product quality or regulatory compliance. Set a defined review window — 15 to 30 business days is common — before the CMO can proceed. And specify that any change requiring a regulatory submission cannot be implemented until Health Canada’s response is received and the filing is complete.

This clause also protects the CMO. When a contract giver’s regulatory team is involved early in change assessment, the risk of an unreviewed change triggering a compliance issue is dramatically reduced for both parties.

Don’t treat annual reviews as a rubber-stamp exercise. Bring both Quality teams to the table, walk through the current manufacturing activities against the QTA scope, and ask directly: does this document still reflect what actually happens? If the answer is no on any point, that’s the observation you’d rather find yourself than have Health Canada find for you.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• Supplier Qualification and COA Verification for Canadian API Imports — Qalitex Laboratories covers raw material testing standards that align with Health Canada GMP expectations for imported pharmaceutical ingredients.
• EU GMP Compliance for Pharmaceutical Manufacturers Entering European Markets — Care Europe’s regulatory team explains how EU Annex 11 and EMA guidance compare to Health Canada’s GMP framework for companies operating across both jurisdictions.